UTMD
Utah Medical Products Inc
74.80$
-0.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 36.6% | 41.5% | 45.5% | 53.0% | 61.0% | 50.0% | 55.7% | 63.3% | 72.6% | 78.5% | 78.6% | 79.8% | |
| 23.8% | 29.5% | 34.4% | 43.0% | 51.2% | 39.0% | 46.2% | 52.7% | 60.6% | 68.6% | 67.7% | 70.0% | |
| 23.8% | 29.5% | 34.4% | 43.1% | 51.2% | 39.0% | 46.2% | 52.7% | 60.6% | 68.6% | 67.7% | 70.0% | |
| 4.8% | 5.8% | 4.2% | 3.9% | 4.0% | 4.3% | 3.7% | 4.4% | 4.5% | 2.5% | 3.3% | 2.9% | |
| 6.0% | 5.3% | 5.9% | 5.7% | 5.4% | 6.3% | 5.6% | 5.7% | 7.1% | 7.1% | 7.2% | 6.5% | |
| 10.2% | 9.3% | 13.0% | 12.5% | 10.4% | 9.8% | 10.1% | 9.5% | 8.3% | – | – | – | |
| 18.7% | 18.6% | 17.6% | 15.2% | 13.7% | 12.7% | 12.7% | 12.2% | 10.8% | 10.1% | 11.1% | 11.5% | |
| 34.6% | 30.6% | 23.8% | 19.2% | 14.8% | 27.5% | 21.5% | 15.4% | 8.4% | 3.7% | 2.3% | 0.7% | |
| 20.4% | 12.0% | 9.6% | 15.8% | 10.8% | 7.9% | 8.0% | 7.3% | 7.8% | 5.3% | 4.2% | 2.7% | |
| 11.1% | 5.1% | 3.9% | 5.7% | 5.3% | 3.1% | 3.4% | 3.2% | 4.8% | 3.5% | 3.1% | 2.1% | |
| 4.8% | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | |
| 1.1% | 0.8% | 1.2% | 1.0% | 1.0% | 1.0% | 0.7% | 0.7% | 1.0% | 0.6% | 0.4% | 0.7% | |
| 1.2% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 79.6% | 88.0% | 90.4% | 84.2% | 89.2% | 92.1% | 92.0% | 92.7% | 92.2% | 94.7% | 95.8% | 97.3% | |
| 80.0% | 92.0% | 105.9% | 92.3% | 100.4% | 100.9% | 99.3% | 99.7% | 101.7% | 102.1% | 105.5% | 105.0% | |
| 4.7% | 4.8% | 4.9% | 4.0% | 3.8% | 3.4% | 3.3% | 3.2% | 2.9% | 2.7% | 2.9% | 2.6% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.